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Microcapsules as assay compartments formed through layer-by-
layer deposition 
Ali Q. Alorabi, a,§ Mark D. Tarn, a, ‡ Martina Stanková, a Vesselin N. Paunov, a and Nicole Pamme *a 
We investigate the potential of using microcapsules, generated through layer-by-layer assembly, as reaction compartments 
for bioassays. A streptavidin-biotin and an esterase-fluorescein diacetate (FDA) assay were employed for proof-of-concept. 
Streptavidin was incorporated into the microcapsules via two methods: (i) physical adsorption onto MnCO3 microcrystal 
templates or (ii) co-precipitation with CaCO3 to form mixed microcrystals. The streptavidin-loaded template microparticles 
were then coated with five bi-layers of polyelectrolytes (polystyrene sulfonate/polyalylamine hydrochloride) (PAH/PSS)5 and 
the templated cores were dissolved using EDTA to form polyelectrolyte microcapsules loaded with streptavidin. Streptavidin 
loading of around 77 mg streptavidin per mol of CaCO3 was achieved using the co-precipitation method, compared to 5.1 
mg streptavidin per mol of MnCO3 using physical adsorption onto the manganese carbonate crystal surface. The 
microencapsulated streptavidin was allowed to bind to an analyte which was able to freely diffuse through the 
polyelectrolyte shell from the aqueous media. Biotin-4-fluorescein was added to the streptavidin-loaded microcapsules, 
with streptavidin-free capsules serving as the control sample. It was found that both types of microcapsules exhibited a 
similar fluorescence signal intensity, likely due to non-specific binding of biotin-4-fluorescein to charged groups on the 
polyelectrolyte shell. Therefore, an alternative esterase-FDA assay was investigated as fluorescence is only produced when 
FDA penetrates the capsule shell and reacts with the esterase enzyme inside which leads to its hydrolysis. Esterase was 
loaded into the LbL capsules templated on CaCO3 via co-precipitation. FDA was added to both the esterase-loaded capsules 
and esterase-free capsules. It was found that the capsules containing esterase fluoresced, while the esterase-free capsules 
did not. This indicates that the hydrolysis reaction of FDA with esterase occurred inside the LbL microcapsules. These 
experiments demonstrate the potential of compartmentalised assays to be carried out inside microcapsules which could be 
applied in complex matrices or in multiplexing experiments, wherein different barcoded microcapsules contain different 
reagents to provide independent readouts without interference from larger biomolecules present in the surrounding media.
Introduction 
Nano- and microcapsules have recently been introduced as drug 
carrier vesicles. Such capsules are fabricated by a layer-by-layer 
(LbL) technique involving the deposition of usually up to ten 
layers of oppositely charged polyelectrolytes (PE) around 
microparticle templates, such as inorganic microcrystals, 
colloidal particles (e.g. latex) or cells, which are eventually 
dissolved by an appropriate solvent or reagent leaving a 
‘hollow’ polyelectrolyte capsule.1 The size of these capsules may 
range from a few nanometres to hundreds of micrometres 
depending on the size and the nature of the template 
employed. 1-3 
LbL capsules are extremely versatile; they may be fabricated 
using organic templates such as polystyrene1,4,5 and melamine 
formaldehyde,6,7 inorganic templates, e.g. SiO24,8 and carbonate 
particles (MnCO3, CdCO3, CaCO3),9, 10 or biological cells, e.g. red 
blood cells11 or yeast cells12,13 and even droplets.14,15 These 
templates can be dissolved by hydrochloric acid (HCl), 
tetrahydrofuran (THF), hydrogen fluoride (HF), ethylene-
diaminetetraacetic acid (EDTA) and sodium hypochlorite 
(NaClO), respectively. The LbL capsule shell can be fabricated 
from diverse charged polymers such as poly(ethyleneimine) 
(PEI), poly(allylamine) (PAH), poly-(diallyldimethylammonium 
chloride) (PDADMAC) and poly-(styrenesulfonate) (PSS).16,17 
The properties of the LbL capsules can be precisely tailored by 
appropriate selection of the core template particles and the 
shell material. LbL capsules have been employed to 
microencapsulate a wide range of materials ranging from small 
molecules18, 19 to macromolecules20-22 for applications in drug 
delivery,23-25 biosensors26, 27 and bioreactors.28,29. 
Release of molecules from the capsules into the surrounding 
medium for drug delivery applications has been a particular 
research focus. More recently, researchers have started to 
explore the penetration of analytes through the multi-layered 
wall into the capsules, to use them as miniature reaction 
a. Department of Chemistry and Biochemistry, University of Hull, Cottingham Road, 
Hull, HU6 7RX, UK. 
§ Current address: Albaha University, Prince Mohammad Bin Saud, Al Bahah 65527, 
Saudi Arabia. 
‡ Current address: School of Earth and Environment, University of Leeds, 
Woodhouse Lane, Leeds, LS2 9JT, UK. 
Electronic Supplementary Information (ESI) available for characterisation of the PE 
layers assembled on the microparticles, synthesis of the calcium carbonate 
microparticles, streptavidin encapsulation efficiencies and the streptavidin-biotin 
assays. See DOI: 10.1039/x0xx00000x 
ARTICLE Journal Name 
2  |  J. Name. , 2012, 00,  1-3  This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
vesicles for analytes of interest to react with biological materials 
that are encapsulated inside the capsules21, 30, 31. For example, 
Caruso et al.21 reported the encapsulation of catalase enzyme 
by coating catalase microcrystals with polyelectrolyte layers. 
The catalase enzymatic activity was preserved and measured by 
exposing the capsules to hydrogen peroxide in the presence of 
protease. The polyelectrolyte shell excluded the large protease 
molecules from the surrounding media, while the hydrogen 
peroxide diffused through the composite PE shell to interact 
with the catalase enzyme and produce water and oxygen. In 
addition, Mak et al.30 developed a method to perform PCR 
inside polyelectrolyte microcapsules. In this method, the PCR 
reagents (polymerase, primers and template) were mixed with 
agarose gel and emulsifier in oil at 40 ℃ to form microdroplets. 
The microdroplet emulsion was cooled to form agarose gel 
microbeads. The microbeads containing the PCR reagents were 
then coated with multiple PE layers to form a polymeric capsule. 
During PCR, small molecular weight building blocks, nucleotides 
(dNTPs), were supplied externally and allowed to diffuse 
through the permeable capsule wall into the interior, while the 
resulting high molecular weight PCR products were 
accumulated within the microcapsule. Moreover, Price et al. 
reported a facile technique for RNA synthesis in LbL 
microcapsules.31 Double-stranded DNA (dsDNA) PCR products 
were adsorbed onto silica colloids followed by LbL assembly of 
thiol-modified PMA (PMASH) and poly-N-vinylpyrrolidone 
(PVPON) via hydrogen bonding. After layering, the PMASH was 
crosslinked and the silica cores were dissolved. Raising the pH 
disrupted the hydrogen bonding between the PMASH and 
PVPON, releasing PVPON from the capsules. Diffusion of T7Pol 
into the capsules initiated transcription from the T7 promoter 
sequence on the dsDNA template. The synthesized RNA 
remained entrapped within the capsules. 
These examples show the potential of performing reactions 
inside LbL microcapsules which allow exclusion of larger 
reactive species from the media. The use of LbL capsules as 
vessels for bioassays has not yet been fully explored. 
Conventional immunoassays are carried out in individual 
reaction tubes or multi-well plates and involve sample pre-
purification steps.32 Miniaturizing immunoassays in LbL 
microcapsules reduces the sample and reagent volumes. Using 
microcapsules as assay vessels also opens the door to running 
many individual or multiplex immunoassays in parallel. The 
capsule wall can act as a protective barrier to prevent larger 
molecules entering and interfering with the assay reaction. In 
the current study, we therefore aimed to investigate the 
potential of LbL microcapsules to act as reaction vessels for 
bioassays (figure 1). Streptavidin-biotin and esterase-diacetate 
fluorescein (FDA) assays were chosen as proof-of-principle 




















Figure 1. Principle of conducting assays in PE microcapsules prepared by the LbL 
method using sacrificial templates. The required reagents were encapsulated 
during the capsule production. Small analyte molecules can penetrate through the 
capsule shell whilst large molecular weight inhibitors are excluded, allowing 
extraction of the analyte from the surrounding media for reaction with the 




Streptavidin, rhodamine red™-X conjugate (lex = 570 nm, lem = 
590 nm), unlabelled streptavidin and biotin-4-fluorescein were 
purchased from Invitrogen Ltd. (UK). Poly(sodium-4-
styrenesulfonate) (PSS) (MW 70kDa, powder), poly(allylamine 
hydrochloride) (PAH) (MW 50kDa, powder), calcium chloride 
(CaCl2), sodium carbonate (Na2CO3), fluorescein diacetate 
(FDA), esterase from Saccharomyces cerevisiae (lyophilized 
powder) and ethylene-diamine-tetraacetic acid disodium salt 
dihydrate (EDTA) were all purchased from Sigma-Aldrich (UK) 
and used as received without further purification. 
 
Preparation of microcapsules from MnCO3 microparticles 
MnCO3 microparticles with a size range of 3-5 µm were 
obtained from PlasmaChem (Germany). The particles were 
suitable for capsule formation through LbL deposition of PSS 
and PAH followed by core dissolution as detailed in ESI1. To 
incorporate streptavidin into the microcapsules, streptavidin 
was deposited as a first layer in the LbL assembly. 50 mg of the 
cationic MnCO3 microcrystals were added to 1 mL of 
fluorescently labelled streptavidin (50 µg mL-1) prepared in 
phosphate buffered saline (PBS) solution (pH8), to ensure a 
negative charge on the streptavidin molecules (pI 5.8). The 
mixture was incubated for 1 h with continuous rotating at 40 
rpm on a tube rotator (Keison Products, UK). The streptavidin-
coated particles were centrifuged at 5,000 rpm for 3 min, the 
supernatant was removed and the particles were washed three 
times with deionised water using centrifugation. Separately, 
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500 μg mL-1 of unlabelled streptavidin was also incubated with 
MnCO3 using the same protocol for use in the streptavidin-
biotin assay. 
This was then followed by PE multilayer deposition. Briefly, 
particles were suspended in 0.5 mL of aqueous NaCl (0.2 M) 
before adding 1 mL of the cationic PAH polyelectrolyte (2 mg 
mL-1). The particles were washed three times with deionised 
water via centrifugation and resuspension, before adding 1 mL 
of anionic polyelectrolyte (PSS) solution (2 mg mL-1). Five 
bilayers of (PAH/PSS) were deposited using this procedure. The 
supernatant and washing solutions were kept for further 
analysis to determine the encapsulation efficiency from 
fluorescence measurements. The MnCO3 cores were dissolved 
with 10 mL EDTA solution (0.3 M) to yield hollow PAH/PSS 
microcapsules. 
 
Preparation of CaCO3 microspheres 
The synthesis of CaCO3 microparticles, the layer-by-layer 
deposition onto CaCO3 microparticles and core dissolution for 
capsule formation were performed and optimised as detailed in 
ESI2. To embed streptavidin in the microcapsules, the protein 
was co-precipitated with the calcium carbonate. First, 100 µL of 
fluorescently labelled streptavidin (1 mg mL-1) was added to 900 
µL of CaCl2 solution (0.37 M). Then 1 mL of Na2CO3 solution (0.33 
M) was poured rapidly into this mixture and stirred at 600 rpm 
for 30 s. With this approach, the streptavidin molecules became 
intercalated within the precipitated CaCO3 particles. Separately, 
to form particles for the streptavidin-biotin assay, 500 µL of 
unlabelled streptavidin (500 μg mL-1) was co-precipitated with 
500 µL CaCl2 (0.66 M) and 1 mL of Na2CO3 (0.33 M), using the 
same protocol.  Similarly, esterase was co-precipitated into 
CaCO3 particles by dissolving 10 mg of esterase in 1 mL of CaCl2 
(0.33 M) before being rapidly mixed with 1 mL of Na2CO3 (0.33 
M) and stirred for 30 s. Subsequently, particles were incubated 
in 1 mL of PAH (1 mg mL-1) under continuous rotation for 15 min. 
The excess PE was removed by three centrifugation and 
washing steps with purified water (6,000 rpm, 3 min). Next, the 
microparticles were dispersed into 1 mL of PSS (1 mg mL-1), 
followed by three rounds of washing. This LbL deposition was 
repeated until the desired number of PE layers was deposited 
on the microparticles. Hollow PE microcapsules were obtained 
by dissolving the CaCO3 core with EDTA (0.3M). 
 
Assay and enzyme reaction protocols  
For the streptavidin-biotin assay, two types of microcapsules 
with six layers of PAH/PSS were used: (i) microcapsules loaded 
with streptavidin (non-fluorescently tagged) as well as (ii) 
microcapsules free of streptavidin as a control. These were 
incubated with 500 µL (in case capsules templated on MnCO3) 
or 50 µL (in case capsules templated on CaCO3) of 0.25 mg mL-1 
of biotin-4-fluorescein for 5 h. The microcapsules were washed 
with water until the fluorescent biotin was removed. For the 
esterase-FDA assay, 10 µL of FDA (10 mg mL-1 in acetone) was 
added to esterase-loaded microcapsules and esterase-free 
microcapsules templated on CaCO3 and then incubated for 10 
min. 
 
Streptavidin encapsulation efficiency 
To determine the streptavidin encapsulation efficiency in the 
MnCO3 and CaCO3 particles, fluorescent streptavidin-
rhodamine red™-X conjugate was employed. The fluorescently 
labelled streptavidin was encapsulated as described above. The 
supernatant containing non-encapsulated streptavidin and all 
PE and washing solutions were collected. The amount of 
fluorescent streptavidin in the supernatants were quantified via 
a fluorescence spectrometer (Perkin Elmer, LS55). The 
encapsulation efficiency (EE %) was calculated as per equation 
1. 
 EE	% = (total	protein− free	protein	in	supernatant)total	protein	 X	100 
 (equation 1) 
 
Capsule characterization  
Confocal Laser Scanning Microscopy (CLSM) images were taken 
using a Zeiss LSM710 inverted confocal microscope (Zeiss, UK) 
equipped with 20x, 40x and 63x oil immersion objectives. 
Samples were prepared by depositing a drop of capsule 
suspension onto a clean glass slide. The excitation wavelength 
was 570 nm for the rhodamine-red™-X conjugate, and 490 nm 
for fluorescein.  
Microcapsule suspensions were also observed under a Nikon 
TE-2000 inverted fluorescence microscope (Nikon, UK), 
equipped with five objectives (2x, 4x, 10x, 20x, 40x). A high 
sensitivity black and white digital CCD camera (Retiga-EXL, 
QImaging, Media Cybernetics, UK) and Image-Pro Plus software 
(Media Cybernetics, UK) were used to capture images.  
Scanning electron microscopy (SEM) was carried out on a Carl 
Zeiss, EVO 60. The particles and microcapsules were washed 
with deionised water to remove salts before pipetting onto a 
glass slide to dry. A thin carbon film was deposited on the 
particle suspension using a vacuum coating machine (Edwards 
High Vacuum, E12 series) prior to imaging.  
The zeta potential of the coated particle templates was 
monitored after each PE absorption step during the LbL 
assembly using a Zetasizer Nano ZS series (Malvern 
Instruments, UK). Particles were dispersed in Milli-Q water 
before the measurement. The reported zeta potential is an 
average of three consecutive measurements. 
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Figure 2 (a) Bright field and (b) confocal microscope images of MnCO3 crystals 
loaded with rhodamine-X-tagged streptavidin through physical absorption on the 
particle surface. (c) Fluorescence intensity profile across the MnCO3 particle. (d) 
Bright field and (e) confocal microscope images of CaCO3 microparticles co-
precipitated with fluorescently labelled streptavidin. (f) Fluorescence intensity 
profile across the CaCO3 particle. 
Results and discussion 
Encapsulation Efficiency of Proteins  
The encapsulation efficiency of rhodamine-streptavidin was 
determined using two approaches. Firstly, the amount of 
encapsulated streptavidin was measured directly via 
fluorescence spectrometry of the particle suspension. Secondly, 
fluorescence within the PE, washing and EDTA solutions was 
measured as an indirect method, since some streptavidin could 
be released during the deposition of PEs and the washing steps, 
as well as during core dissolution with EDTA. 
The encapsulation efficiency of streptavidin on MnCO3 
microparticles was investigated by incubating them with 
fluorescently tagged streptavidin for 1 h. Subsequently, five 
bilayers of (PAH/PSS) PE were assembled on the particles. 
Figures 2a and 2b show bright field and fluorescence CLSM 
images, respectively, for the PE-coated microparticles with 
encapsulated fluorescent streptavidin. These illustrate the 
absorption of streptavidin predominately on the external 
surface of the MnCO3 crystals. The streptavidin did not 
penetrate inside the core as seen in the CLSM image (fig 2b) and 
the fluorescence intensity profile through the particle (fig 2c). 
We also produced CaCO3 particles loaded with fluorescent 
streptavidin through co-precipitation from Na2CO3 and CaCl2 as 
described in the experimental section. The streptavidin-loaded 
CaCO3 particles were washed with Milli-Q water to remove 
unbound streptavidin before visualisation. The particles were of 
spherical shape with a fairly narrow size distribution (4 ± 1 μm) 
(see SEM images, figure S-2.1 in the ESI). Figures 2d and 2e show 
bright-field and fluorescence microscopy images, respectively, 
indicating that the streptavidin was embedded successfully. The 
distribution of the fluorescent streptavidin was observed with 
CLSM (fig 2e) showing streptavidin throughout the entire 
volume of the CaCO3 particles. This is further corroborated by 
the intensity plot (figure 2f) exhibiting a constant fluorescence 
intensity profile across the particle diameter. 
The streptavidin-loaded microparticles (MnCO3 and CaCO3) 
were coated with five bilayers of (PAH/PSS), followed by 
dissolution of the core with EDTA (figure 3). There was no 
noticeable difference in the shape or dimension of 
microcapsules following the MnCO3 core dissolution. 
Interestingly, for the MnCO3 templated capsules, the 
streptavidin was localised in the PE shell rather than being 
distributed evenly throughout the capsule cavity (fig 3b). The 
fluorescence intensity profile across the microcapsules showed 
a high fluorescence intensity at the edge of the microcapsule 
shell, which decreased as it approached the capsule’s centre 
(figure 3c). A similar effect was seen for the CaCO3-based 
capsules (fig 3 d-f). This indicates that the streptavidin is likely 
to be attached to the PE shell.  
For MnCO3, it was found that 5.3% of total utilised streptavidin 
(50 μg) adhered to the microparticles, which was reduced to 
4.4% during the PE deposition and washing steps (see ESI 3.1, 
figure S3.1 and S3.2). Once the PE layers were deposited, it was 
found that only a negligible amount of streptavidin escaped 
during core dissolution with EDTA indicating the feasibility of 
retaining larger molecular weight compounds inside the 
capsule. The trapping efficiency can be estimated at 51 mg 
streptavidin per mol of MnCO3. For the CaCO3 particles, it was 
found that 94% of the utilised streptavidin (100 μg) was 
entrapped inside the co-precipitated crystals (see ESI 3.2, 
figures S3-3 and S3-4). During the LbL deposition with PE and 
washing steps, this was further reduced to 51%. Once again, the 
particle template dissolution via EDTA solution did not lead to 
further streptavidin losses (see figure S-2.2,  in ESI). The trapping 
efficiency can be estimated at 77 mg streptavidin per mol of 
CaCO3. 
 
LbL microcapsules for streptavidin-biotin assay 
The streptavidin-biotin assay experiments were conducted with 
capsules templated on MnCO3 and CaCO3 particles. Two types 
of microcapsules were fabricated: (i) microcapsules not 
containing any streptavidin as control, and, (ii) microcapsules 
with (non-fluorescent) streptavidin. Both kinds of 
microcapsules were incubated with biotin-4-fluorescein 
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Figure 3 (a) Bright field and (b) confocal microscope images of LbL-coated MnCO3 
microparticles following dissolution of the particle core with EDTA. The particles 
had been prepared by physically adsorbing rhodamine-X-labelled streptavidin 
onto the particles surface. (c) Fluorescence intensity profile across the MnCO3 
particle. (d) Bright field and (e) confocal microscope images of LbL-coated CaCO3 
microparticles, following dissolution of the core with EDTA. The core particles had 
been prepared via co-precipitation of CaCO3 with fluorescently tagged 
streptavidin. (f) Fluorescence intensity profile across an individual CaCO3 
microcapsule. 
It was found that both microcapsules containing streptavidin as 
well as microcapsules entirely free of streptavidin exhibited a 
fluorescence signal, indicating binding of fluorescently-tagged 
biotin to the PE capsules regardless of whether streptavidin was 
present or absent. The fluorescence was localised on the 
capsule shells, compared to the interior of the capsules, as 
illustrated by the fluorescence intensity profile plotted across 
the centre of the PE capsules (see ESI4). This would indicate that 
the biotin-4-fluorescein adsorbed onto the capsule PE shell 
rather than freely penetrating into the capsule interior to bind 
to streptavidin specifically. The negatively charged fluorescein-
tagged biotin, upon binding to the cationic polyelectrolyte 
component of the PE shell, would prevent the biotin molecules 
from entering and interacting with the streptavidin inside the 
capsule. To overcome this issue, we designed a different 
experiment with a non-ionisable molecule (fluorescein 
diacetate) which is hydrolysed by an esterase enzyme inside the 
microcapsules upon hydrolysis. 
 
LbL microcapsules for esterase-fluorescein diacetate (FDA) 
reaction 
The esterase enzyme was encapsulated in CaCO3 particles via 
co-precipitation as outlined in the experimental section. The 
esterase-loaded CaCO3 particles were then coated with 
alternating anionic and cationic PE layers and, after the desired 
number of PEs layers were deposited, the cores were dissolved 
with EDTA to form hollow PE microcapsules with entrapped 
esterase. As a control, PE microcapsules free of esterase were 
also fabricated using the same protocol. Both types of PE 
microcapsules, esterase-free and esterase-loaded, were 
incubated with a FDA solution. As can be seen in figure 4a-b, the 
esterase-free microcapsule exhibited no fluorescence after 
adding the FDA solution, whereas the esterase-containing 
capsules showed a fluorescence signal (figure 4c-d). The non-
fluorescent FDA molecules, after diffusion into the 
microcapsule, were hydrolysed by the esterase enzyme to form 
a fluorescent product, fluorescein. This product was not formed 
in the capsules free of esterase enzyme. The enzyme-filled 
microcapsules were imaged with a confocal fluorescence 
microscope (figure 4e-f). The intensity plot across a capsule 
(figure 4g) indicates fluorescence on/inside the shell as well as 
to some degree inside the capsule. The hydrolysis of FDA to 
fluorescein was successfully demonstrated in the 
microcapsules. However, it was difficult to determine enzyme 
localisation in the capsules. The enzyme may have been located 
in the capsule’s centre where the FDA converted to a negatively 
charged fluorescein. In such a case, the fluorescein would have 
bound to the cationic PEs on the capsule’s internal shell. 
Another, more realistic possibility is that the esterase enzyme is 
attached to the inner PE shell, just as was found with the 
streptavidin, and the incoming FDA is hydrolysed there, where 
the produced fluorescein also gets deposited. 
The observed result was in agreement with studies by other 
authors using PE microcapsules to immobilise enzymes inside a 
microcapsule cavity or within PE shells.21, 28, 33, 34 We have here 
shown the ability of the system to perform an assay and an 
enzyme reaction which can be adapted for drug concentration 
determination by immobilising antibody (protein) in the PE 
capsules, whilst allowing small analyte molecules (drug) in the 
sample to penetrate the PE shell to interact with the 
immobilized protein. Such microcapsule assays could be used 
for conducting a large number of individual assays in parallel on 



















Figure 4 (a) Bright field and (b) fluorescence microscopy images of esterase-free 
microcapsules following the reaction with FDA. (c) Bright field and (d) fluorescence 
microscopy images of esterase-loaded microcapsules following the reaction with 
FDA, showing the formation of the fluorescent product (fluorescein) in the PE 
capsule. (e) Bright field and (f) fluorescence CLSM images of the esterase-loaded 
microcapsules following reaction with FDA. (g) Fluorescence intensity profile 
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Conclusions 
The encapsulation of streptavidin and esterase into PE 
microcapsules fabricated from multiple bilayers of PAH/PSS 
onto inorganic crystal templates was demonstrated. A biotin-
streptavidin assay and an FDA-esterase specific reaction were 
investigated with these capsules. The biotin-streptavidin assay 
revealed that biotin was found to bind non-specifically to the PE 
shell surface and did not penetrate freely into the capsule. For 
the FDA-esterase reaction, the non-fluorescent starting 
molecule FDA was used as an analyte model and added to both 
esterase-filled and esterase-free microcapsules. When the FDA 
diffused through the microcapsule shell, the esterase enzyme 
hydrolysed the incoming FDA to fluorescein. This fluorescent 
product was only observed in the esterase-loaded capsules. This 
proof-of-concept experiment shows the potential for 
performing assays for example for drug testing by immobilising 
specific antibodies inside the PE microcapsule while small 
sample analytes are allowed to penetrate the capsule shell. Our 
findings tie in with previous literature reports on enzymatic 
reactions carried out inside such capsules namely catalase for 
reaction with penetrating hydrogen peroxide21 and PCR with 
penetrating nucleotide building blocks.30 Microcapsules could 
react as containers for challenging matrices that may contain 
inhibiting substances such as environmental soil and water 
samples and biological samples including stool and urine 
samples. The method only requires a small volume of sample, 
the binding reaction is protecting from inhibiting larger size 
molecules that may be present in the sample and cannot 
penetrate the capsule shell. Using different coloured or 
fluorescently-tagged labels, the capsules have the potential to 
allow parallel analysis of several analytes for multiplex assays.  
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1. Characterisation of polyelectrolyte assembly on manganese 
carbonate particles (MnCO3) 
Layer-by-layer assembly was performed on MnCO3, crystals ranging in diameter from 3 to 5 μm 
(PlasmaChem, Germany). 50 mg of the dry particles were dispersed in 1 mL of purified water for 
washing. The particles were vortexed and then collected by centrifugation at 5000 rpm for 3 min. The 
supernatant was pipetted off before being replaced with 1 mL of fresh water. 500 μL of this particle 
suspension was added to 500 μL of the anionic polyelectrolyte PSS (2 mg mL-1) in a 1.5 mL Eppendorf 
tube and incubated for 20 min under continuous rotation at 40 rpm on a tube rotator. The coated 
microparticles were centrifuged at 600 rpm for 2 min; the supernatant was removed and the particles 
were washed three times with deionised water to ensure the removal of free PEs. The negatively 
charged coated particles were then re-suspended in 500 μL of NaCl (0.5 M) before adding the 
positively charged second PE, PAH-FITC (2 mg mL-1) (figure S1.1). The same protocol was repeated to 
deposit ten layers of alternatingly charged PEs (PSS/PAH-FITC) on the magnetic particles. EDTA 
solution (0.3 M) was used to dissolve the particle cores. 
As shown in figure S1.2(a), the zeta potential alternated as oppositely charged PE layers were 
deposited on the particle cores. The fluorescence intensity was found to increase with the number of 
fluorescently-tagged PE layers (FITC-PAH) deposited (figure S1.2(b)). SEM images of the MnCO3 cores 
before the LbL coating and of the collapsed hollow-shell PE capsules after the MnCO3 core removal 
are shown in figures S1.2(c-d). Microparticles coated with five bi-layers of FITC-PAH/PSS were also 
captured with fluorescence microscopy (figure S1.2(e)) and confocal microscopy (figure S1.2(f)) 





Figure S1.1 Schematic of the coating of MnCO3 particles with alternating PE assembly of FITC-PAH and 
PSS. The MnCO3 particles were exposed to a fluorescently-labelled, positively charged PE (FITC PAH) to 
deposit the first PE layer. The excess PE was removed by the cycles of centrifugation and washing steps 






Figure S-1.2 PE layers deposited onto MnCO3 crystals. (a) The zeta potential changes from positive to a 
negative demonstrating the alternating particle surface charge. (b) Fluorescence intensity plotted as a 
function of the fluorescent FITC-PAH layer number; the fluorescence increased indicating the successful 
PE film growth. (c) SEM image of the MnCO3 cores before LbL coating and (d) collapsed hollow PE 
capsules after the MnCO3 was removed with EDTA solution. (e) Fluorescence image of MnCO3 particles 





2. Characterisation of polyelectrolyte assembly on calcium carbonate 
particles (CaCO3) 
Synthesis of calcium carbonate microparticles (CaCO3)  
Calcium carbonate microparticles (CaCO3) were synthesised using procedures developed in the 
literature1, 2. Briefly, 1 mL of aqueous Na2CO3 solution (0.33 M) was poured rapidly into 1 mL of 
aqueous CaCl2 solution (0.33 M) and mixed with a magnetic stirrer at 600 rpm for different periods of 
time (1 min, 5 min, 1 h, 2 h, 3 h) to study the effect of mixing time on particle morphology. The 
agitation was stopped and the particles were left for 10 min before washing three times with water. 
For this, the particle suspension was pipetted in an Eppendorf tube and vortexed for 15 s. The particles 
were collected via centrifuge at 5,000 rpm for 3 min, and finally the supernatant was removed and 
replaced with purified water. The CaCO3 particles were re-suspended in 0.5 ml of 0.5M NaCl prior to 
the PE assembly (section 2.2). For SEM imaging (figure S2.1) the particles were thoroughly washed 
with purified water to remove the NaCl. The formation of uniform, nearly spherical CaCO3 
microparticles with narrow size distribution (4 ± 1 μm) was observed at a short mixing time (30 s) of 
Na2CO3 and CaCl2; this condition was chosen for PE assembly. 
 
 
Figure S-2.1 SEM images of CaCO3 microparticles obtained after different stirring periods during the synthesis 
process. (a) Spherical particles (vaterite) crystals obtained after mixing for 1 and (b) 5 min; (c) a mixture of spherical 
particles (vaterite) and rhombohedral microcrystals (calcite) obtained after stirring for 1 h; (d) rhombohedral 
microcrystals (calcite) obtained when stirring for 2 h and (e) 3 h. (f) Calcite microcrystal amount (%) as a function of 




PSS/PAH assembly on calcium carbonate particles (CaCO3) 
The process of LbL assembly of PE layers on the calcium carbonate particles is laid out in figure S2.2. 
300 µL of CaCO3 particle stock suspension were incubated in 1 mL of PAH polyelectrolyte (1 mg mL-1) 
under continuous rotation for 15 min. The excess of PE was removed by three centrifugation and 
washing cycles with purified water (6,000 rpm, 3 min). Next, the microparticles were dispersed into 1 
mL of PSS polyelectrolyte (1 mg mL-1), followed by three rounds of washing. This LbL deposition was 
repeated until the desired number of PE layers were deposited on the microparticles. Zeta potential 
measurements and microscopy images confirm the layer deposition as shown in figure S2.3. 
Hollow-shell PE microcapsules were obtained by dissolving the CaCO3 core with EDTA. Different 
volumes of EDTA were added to the CaCO3 particles and incubated for varying times to optimise the 
core dissolution. In the first experiment, 1 mL of fresh EDTA (0.3 M) was added to the coated CaCO3 
particles and vortexed for 2 h followed by centrifugation (1,200 rpm for 10 min) and re-dispersion in 
1 mL of fresh EDTA. This step was repeated three times to ensure all particles had dissolved before 
the final rinse with purified water. In an alternative experiment, 10 mL of EDTA (0.3 M) were added to 
the particles and incubated for 20 h before the supernatant was removed and replaced with water. 




Figure S2.2 Schematics of the preparation and coating of the CaCO3 particles with alternating layers of 





Figure S-2.3 LbL deposition of PE (PSS/FITC-PAH)5 on CaCO3 microparticles. (a) The particles zeta potential alternates 
as a function of the number PE layers deposited (n=3). (b) Bright field image and (c) fluorescence microscope image 
of CaCO3 microparticles coated with 10 layers of FITC-PAH/PSS polyelectrolyte. 
 
 
Figure S-2.4 SEM images of LbL formed PE microcapsules with particles core dissolved by EDTA solution. (a) Two-
bilayered PE microcapsules forming a thinner shell. (b) Six-bilayer PE microcapsules with a thicker shell. (c) Ten-
bilayer PE CaCO3 particles with the majority of CaCO3 cores not dissolved.  
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3. Streptavidin encapsulation efficiency in polyelectrolyte 
microcapsules templated on MnCO3 or CaCO3 




Figure S-3.1 Streptavidin was loaded directly onto the MnCO3 microparticles, followed by deposition of alternating 
layers of polyelectrolytes, namely the cationic PAH and the anionic PSS.  Five bilayers were deposited.  
 
 
Figure S-3.2 (a) Calibration curve of Rhodamine Red™-X conjugated streptavidin. (b) The encapsulation efficiency 
(in %) of Rhodamine Red™-X conjugated streptavidin measured directly from the particle suspension. (c) Loss of 
streptavidin during the deposition of PE layers and core dissolution with EDTA solution. The magnified cross section 
shows the encapsulation efficiency (in %) of fluorescent streptavidin measured through streptavidin released into 
PE, washing and EDTA solutions. 
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Streptavidin incorporation into capsules made from CaCO3 microspheres 
 
Figure S-3.3 Schematic of the method to encapsulate streptavidin inside CaCO3 particles via the co-precipitation, 
followed by LbL assembly of PAH/PSS polyelectrolytes. During core formation, streptavidin is co-precipitated inside 
the CaCO3 microparticles. PAH, a polycation PE, is deposited as the first layer. Excess PE is removed via washing 
before the second PE layer, PSS (a polyanion PE), is deposited. The core is then dissolved by EDTA to leave hollow 
capsules loaded with streptavidin. 
 
 
Figure S-3.4 (a) Calibration curve for rhodamine-conjugated streptavidin. Encapsulation efficiency (in %) of 
fluorescent streptavidin was measured (b) directly from the particle suspension, or (c) by the amount of streptavidin 








Figure S-4.1 Concept of streptavidin-biotin assay in LbL capsules templated from MnCO3 and CaCO3 microparticles. 
(a) Biotin-4-fluorescein solution was added to capsules not containing streptavidin as a control and (b) to PE 
capsules filled with streptavidin. 
 
 
Figure S-4.2 Streptavidin-biotin assay performed in microcapsules templated on MnCO3 particles. (a, b) 
Fluorescence CLSM images of streptavidin-free microcapsules. (c) Fluorescence intensity profile for line plotted 
across streptavidin-free microcapsules. (d) Low magnification fluorescence CLSM image of streptavidin-loaded 
microcapsules. (e) High magnification fluorescence CLSM image of streptavidin-loaded microcapsules. (f) 
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